Pharmacokinetics of Enoxaparin in Intensive Care Patients

Summary

To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered either as a continuous intravenous infusion or subcutaneous bolus once daily. To investigate possible ongoing coagulation by coagulation markers during antithrombotic therapy with standard doses of enoxaparin

Timeline

Start

2014-03

Primary completion

2016-06-30

Completion

2016-09-30

Drugs

Indications